Date: 2014-12-22
Type of information: Development agreement
Compound: BIO4
Company: Osiris Therapeutics (USA - MD ) Stryker (USA - MI)
Therapeutic area: Regenerative medicine
Type agreement: development commercialisation
Action mechanism: BIO4 is a bone allograft that contains both viable cells and growth factors. It is a safe alternative to autografts that minimizes the potential for harvest site co-morbidities. BIO4 is composed of a structural extracellular matrix, osteogenic and angiogenic growth factors, endogenous mesenchymal stem cells and osteoblasts. It possesses osteoconductive, osteoinductive, osteogenic and angiogenic properties that are required for bone repair and regeneration. BIO4 was developed by Osiris Therapeutics, utilizing their proprietary Biosmart® cryopreservation technology. Originally branded as OvationOS®, Osiris\' viable bone matrix tissue form will now be marketed by Stryker under the brand name BIO4.
Disease:
Details: * On December 22, 2014, Osiris Therapeutics, a cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced that it has entered into an exclusive, worldwide partnership with Stryker Corporation for the commercialization and development of Osiris\' viable bone matrix tissue form. Stryker is a global leader in medical technology whose products and services are available in over 100 countries around the world. This partnership strategically aligns one of Osiris\' leading regenerative medicine technologies with Stryker\'s innovative medical device portfolio; the resulting synergies will maximize the market potential. The Agreement provides Stryker with exclusive, worldwide rights to Osiris\' viable bone matrix under the name BIO4 ™. Osiris will be responsible for the manufacturing, continued research and product improvement activities while Stryker will be responsible for the commercialization and marketing of BIO4. To demonstrate the differentiating benefits and ensure the continued success and growth of this innovative product, both organizations will collaborate on the design and conduct of future clinical development programs.
Financial terms:
Latest news:
